In July 2020, Carolyn Bertozzi, Ph.D. and her team at Stanford University published a transformational paper that characterized a new class of molecules called lysosome-targeting chimeras, or LYTACs. In the paper, Dr. Bertozzi and her team described a new method of engineering an antibody to shuttle a targeted extracellular protein into the lysosome, a cellular component inherently responsible for degradation. Versant Ventures subsequently licensed the technology, and Lycia, ultimately, was born.
Read Dr. Bertozzi’s original paper on LYTACs and learn how Lycia has continued to evolve this novel technology to expand its potential applications.
Learn more about our platform.